CCCC C4 Therapeutics Inc
Company Analysis
Latest News
🟢 C4 Therapeutics Inc up 5.2% amid Goldman Sachs Healthcare Conference participation
C4 Therapeutics Inc is trading at $3.77 (5.2%) in pre-market amid management's participation in a major investor conference. • The company is scheduled to...
🟢 C4 Therapeutics Inc is trading 7.2% up today on a technical recovery after a recent pullback
C4 Therapeutics Inc is trading at $3.85 (+7.2%), rebounding after a sharp multi-session pullback following its late-May/early-June rally. • The stock has...
🔴 C4 Therapeutics Inc is trading 6.3% down today on profit-taking and high volatility after recent rally
C4 Therapeutics Inc is trading at $3.61 (down 6.3%) as the stock extends a multi-session pullback following a strong rally in late May and early June. •...
🔴 C4 Therapeutics Inc is trading 5.3% down today on profit-taking and broader risk-off sentiment
C4 Therapeutics Inc is trading at $3.95 (5.3% down) as the stock pulls back following a sharp multi-day rally and recent analyst upgrades that had previously...
C4 Therapeutics Gains Analyst Upgrades on Cemsidomide Progress
C4 Therapeutics received upgraded analyst ratings in early June 2026. Zacks issued a 'Buy' rating on June 1. These upgrades reflect an upward trend in earnings...
🟢 C4 Therapeutics Inc is trading 6.57% up
CCCC is trading at $4.22, up 6.57%.
🟢 C4 Therapeutics Inc is trading 8.08% up
CCCC is trading at $4.28, up 8.08%.
🟢 C4 Therapeutics Inc is trading 8.84% up
CCCC is trading at $4.31, up 8.84%.
🟢 C4 Therapeutics Inc is trading 11.74% up
CCCC is trading at $4.42, up 11.74%.
C4 Therapeutics Price Target Increased to $12.00 by Evercore ISI
On June 1, 2026, Evercore ISI Group reaffirmed its positive outlook on C4 Therapeutics (NASDAQ: CCCC). The investment bank maintained an "Outperform" rating on...